May 26, 2020 06:38 AM EDTUpdated 10:40 AM

Pivotal myasthenia gravis data from argenx augur well for FcRn inhibitors in development

Natalie Grover

Reporter

Leading the pack of biotechs vying for a piece of the generalized myasthenia gravis (gMG) market with an FcRn inhibitor, argenx on Tuesday unveiled keenly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pivotal myasthenia gravis data from argenx augur well for FcRn inhibitors in development

Natalie Grover

Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

US warns drugmakers against misrepresenting cost of imported products

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Piv­otal myas­the­nia gravis da­ta from ar­genx au­gur well for FcRn in­hibitors in de­vel­op­ment

Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pivotal myasthenia gravis data from argenx augur well for FcRn inhibitors in development